Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases

CONCLUSIONS: This study illustrates the feasibility of detecting alterations from ctDNA among patients with BrMs. A higher frequency of actionable mutations was observed in ctDNA in patients with BrMs. Additional studies comparing ctDNA and alterations in BrMs tissue are needed to determine if ctDNA can be considered a surrogate to support treatment decisions.PMID:38680992 | PMC:PMC11046982 | DOI:10.1093/noajnl/vdae052

Source: Adv Data - April 29, 2024 Category: Epidemiology Authors: Laura Alder Gloria Broadwater Michelle Green Amanda E D Van Swearingen Eric S Lipp Jeffrey Melson Clarke Carey K Anders Sarah Sammons Source Type: research